文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

增强型不稳定血浆铁与急性髓系白血病及骨髓增生异常综合征异基因造血细胞移植后的结局(ALLIVE):一项前瞻性、多中心、观察性试验

Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial.
PubMed 文献 · Lancet Haematol · 2018-04-05

ALLIVE 前瞻性多中心观察性试验在德国五个中心纳入 112 例接受异基因造血细胞移植的急性髓系白血病或骨髓增生异常综合征患者,评估储存铁(MRI 肝铁含量)与生物活性铁(增强型不稳定血浆铁 eLPI)对移植后结局的预测价值。移植前肝铁含量与 eLPIdyn 无显著相关(ρ=0.116,p=0.22);预处理期间 eLPI 迅速升高,108 例中 79 例(73%)在移植日 eLPI 升高。移植前肝铁含量≥125 μmol/g 者第 100 天非复发死亡率 20%(95%CI 14-26),高于低浓度者的 7%(2-12;p=0.039);基线 eLPI 升高者第 100 天非复发死亡率 33%(15-52),高于基线 eLPI 正常者的 7%(2-13;p=0.00034)。作者认为 eLPI 可能是铁相关毒性的生物学介质。

要点

  • 移植前肝铁含量与 eLPIdyn 无显著相关(ρ=0.116,p=0.22)。
  • 108 例中 79 例(73%)在移植日出现 eLPI 升高。
  • 移植前肝铁含量≥125 μmol/g 者第 100 天非复发死亡率 20% vs 低浓度者 7%(p=0.039)。

核心结论

  • eLPI 可能是铁相关毒性的生物学介质。
  • 围移植期 eLPI 清除策略可在前瞻性干预性临床试验中针对全身性铁过载患者进行探索。

研究设计与样本

  • 前瞻性、多中心、观察性 ALLIVE 试验在德国五个中心招募患者。
  • 纳入接受异基因造血细胞移植的急性髓系白血病或骨髓增生异常综合征患者。
  • 患者接受细胞毒性预处理中位 6 天(IQR 6-7)后行异基因造血细胞移植,移植后随访长达 1 年(±3 个月)。
  • 2012 年 12 月 13 日至 2014 年 12 月 23 日期间 112 例患者接受异基因造血细胞移植。
  • 主要终点为异基因造血细胞移植期间 eLPI 动力学的定量描述,以及移植前肝铁含量与动态 eLPI(eLPIdyn;最大 eLPI 减基线 eLPI)之间的相关系数。

主要发现

  • 移植前肝铁含量与 eLPIdyn 无显著相关(ρ=0.116,p=0.22)。
  • 血清 eLPI 浓度在预处理期间迅速升高,108 例中 79 例(73%)在移植日 eLPI 升高。
  • 移植前肝铁含量大于或等于 125 μmol/g 者第 100 天非复发死亡率 20%(95%CI 14-26),高于低浓度者的 7%(95%CI 2-12;p=0.039)。
  • 基线 eLPI 升高者第 100 天非复发死亡率 33%(95%CI 15-52),高于基线 eLPI 正常者的 7%(95%CI 2-13;p=0.00034)。

关键数值与推荐

  • eLPI 以 FeROS eLPI 试剂盒(Aferrix,Tel-Aviv,Israel)在血清样本中测定,大于 0.4 μmol/L 视为 eLPI 升高。
  • 肝铁含量以 MRI 测定。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of systemic iron overload on outcomes after allogeneic haemopoietic cell transplantation (HCT) has been a matter of substantial debate. We aimed to investigate the predictive value of both stored (MRI-derived liver iron content) and biologically active iron (enhanced labile plasma iron; eLPI) on post-transplantation outcomes in patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogenic HCT. METHODS: The prospective, multicentre, observational, ALLogeneic Iron inVEstigators (ALLIVE) trial recruited patients at five centres in Germany. We enrolled patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogeneic HCT. Patients underwent cytotoxic conditioning for a median of 6 days (IQR 6-7) before undergoing allogeneic HCT and were followed up for up to 1 year (±3 months) post-transplantation. eLPI was measured in serum samples with the FeROS eLPI kit (Aferrix, Tel-Aviv, Israel) and values greater than 0·4 μmol/L were considered to represent raised eLPI. Liver iron content was measured by MRI. The primary endpoints were the quantitative delineation of eLPI dynamics during allogeneic HCT and the correlation coefficient between liver iron content before HCT and dynamic eLPI (eLPIdyn; maximum eLPI minus baseline eLPI). All patients with available data were included in all analyses. This is the final analysis of this completed trial, which is registered with ClinicalTrials.gov, number NCT01746147. FINDINGS: Between Dec 13, 2012, and Dec 23, 2014, 112 patients underwent allogeneic HCT. Liver iron content before allogeneic HCT was not significantly correlated with eLPIdyn (ρ=0·116, p=0·22). Serum eLPI concentrations rapidly increased during conditioning, and most (79 [73%] of 108) patients had raised eLPI by the day of transplantation. Patients with a pretransplant liver iron content greater than or equal to 125 μmol/g had an increased incidence of non-relapse mortality (20%, 95% CI 14-26) compared with those with lower concentrations (7%, 2-12; p=0·039) at day 100. Patients who had raised eLPI at baseline also had a significantly increased incidence of non-relapse mortality at day 100 (33%, 15-52) compared with those who had normal eLPI at baseline (7%, 2-13; p=0·00034). INTERPRETATION: eLPI is a possible biological mediator of iron-related toxicity. Peritransplantation eLPI-scavenging strategies could be explored in prospective interventional clinical trials for patients with systemic iron overload. FUNDING: The Technical University of Dresden and Novartis.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Wermke M, Eckoldt J, Götze KS, et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematol. 2018. PMID: 29628397. doi:10.1016/S2352-3026(18)30036-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。